PG102P控制血液透析患者瘙痒的安全性和有效性(SNUG试验):一项随机对照试验的研究方案
SNUG是一项多中心、随机、双盲、安慰剂对照临床试验,计划纳入80例血液透析患者,按1:1随机分为PG102P 1.5 g/日组或安慰剂组,治疗8周后观察2周。主要终点为组间治疗前后视觉模拟评分的差异,次要结局包括血清总免疫球蛋白E、嗜酸性粒细胞阳离子蛋白、钾、钙、磷、全段甲状旁腺激素及血嗜酸性粒细胞计数等。
要点
- PG102P由软枣猕猴桃(Actinidia arguta)制备,具有对瘙痒的免疫调节作用。
- 主要终点为组间治疗前后视觉模拟评分(VAS)的差异。
- 治疗8周后设2周观察期,期间所有患者维持原抗瘙痒治疗。
核心结论
- SNUG研究旨在探讨PG102P改善血液透析患者瘙痒的抗瘙痒效果。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照临床试验,计划纳入80例血液透析患者。
- 患者按1:1比例随机分为治疗组(PG102P 1.5 g/日)或对照组(安慰剂)。
- 治疗持续8周,随后2周观察期;观察期内所有患者维持先前使用的抗瘙痒治疗。
主要发现
- 主要终点为组间治疗前后视觉模拟评分的差异。
- 次要结局包括第0周至第8周血清总免疫球蛋白E、嗜酸性粒细胞阳离子蛋白、钾、钙、磷、全段甲状旁腺激素水平及血嗜酸性粒细胞计数。
- 将进行肾脏疾病与生活质量问卷及贝克抑郁量表评估。
- 还将评估安全性及发生的任何不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pruritus in patients undergoing hemodialysis is a highly prevalent complication that affects quality of life. Several medications are currently used for the treatment of uremic pruritus, but these are not satisfactory. PG102P, which is prepared from Actinidia arguta, has an immune-modulating effect on pruritus. This trial is designed to assess the antipruritic effect of PG102P compared with placebo. METHODS: This multicenter, randomized, double-blind, placebo-controlled clinical trial will include 80 patients undergoing hemodialysis. The patients will be randomized in a 1:1 ratio to a treatment group (PG102P 1.5 g/day) or a control group (placebo). The treatment will last for 8 weeks, followed by a 2-week observational period. During the observational period, all of the patients will maintain the antipruritic treatment previously used. The primary endpoint will be measured as the difference in visual analog scale between the groups before and after treatment. Secondary outcomes include serum levels of total immunoglobulin E, eosinophil cationic protein, potassium, calcium, phosphorus, intact parathyroid hormone, and blood eosinophil count between weeks 0 and 8. Kidney Disease and Quality of Life and Beck's Depression Inventory questionnaires will be conducted. Safety assessments and any adverse events that occur will also be evaluated. DISCUSSION: The SNUG is a clinical study that aims to investigate the antipruritic effect of PG102P to ameliorate itching in patients undergoing hemodialysis. TRIAL REGISTRATION: Clinical Trials.gov, NCT03576235. Registered on 4 July 2018.
引用
- Kim YC, Park JY, Oh S, et al. Safety and efficacy of PG102P for the control of pruritus in patients undergoing hemodialysis (SNUG trial): study protocol for a randomized controlled trial. Trials. 2019. PMID: 31779697. doi:10.1186/s13063-019-3753-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。